PMID- 29928442
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230926
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 1
DP  - 2018 Jul
TI  - A novel potential effective strategy for enhancing the antitumor immune response 
      in breast cancer patients using a viable cancer cell-dendritic cell-based 
      vaccine.
PG  - 529-535
LID - 10.3892/ol.2018.8631 [doi]
AB  - Dendritic cells (DCs) have been used in a number of clinical trials for cancer 
      immunotherapy; however, they have achieved limited success in solid tumors. 
      Consequently the aim of the present study was to identify a novel potential 
      immunotherapeutic target for breast cancer patients through in vitro optimization 
      of a viable DC-based vaccine. Immature DCs were primed by viable MCF-7 breast 
      cancer cells and the activity and maturation of DCs were assessed through 
      measuring CD83, CD86 and major histocompatibility complex (MHC)-II expression, in 
      addition to different T cell subpopulations, namely CD4(+) T cells, CD8(+) T 
      cells, and CD4(+)CD25(+) forkhead box protein 3 (Foxp3)(+) regulatory T cells 
      (Tregs), by flow cytometric analysis. Foxp3 level was also measured by 
      enzyme-linked immunosorbent assay (ELISA) in addition to reverse-transcription 
      quantitative polymerase chain reaction. The levels of interleukin-12 (IL-12) and 
      interferon-gamma (IFN-gamma) were determined by ELISA. Finally, the cytotoxicity of 
      cytotoxic T lymphocytes (CTLs) was evaluated through measuring lactate 
      dehydrogenase (LDH) release by ELISA. The results demonstrated that CD83(+), 
      CD86(+) and MHC-II(+) DCs were significantly elevated (P<0.001) following priming 
      with breast cancer cells. In addition, there was increased activation of CD4(+) 
      and CD8(+) T-cells, with a significant decrease of CD4(+)CD25(+)Foxp3(+) Tregs 
      (P<0.001). Furthermore, a significant downregulation of FOXP3 gene expression 
      (P<0.001) was identified, and a significant decrease in the level of its protein 
      following activation (P<0.001) was demonstrated by ELISA. Additionally, 
      significant increases in the secretion of IL-12 and IFN-gamma (P=0.001) were 
      observed. LDH release was significantly increased (P<0.001), indicating a marked 
      cytotoxicity of CTLs against cancer cells. Therefore viable breast cancer 
      cell-DC-based vaccines could expose an innovative avenue for a novel breast 
      cancer immunotherapy.
FAU - Abdellateif, Mona S
AU  - Abdellateif MS
AD  - Medical Biochemistry and Molecular Biology Unit, Department of Cancer Biology, 
      National Cancer Institute, Cairo University, Cairo 11976, Egypt.
FAU - Shaarawy, Sabry M
AU  - Shaarawy SM
AD  - Medical Biochemistry and Molecular Biology Unit, Department of Cancer Biology, 
      National Cancer Institute, Cairo University, Cairo 11976, Egypt.
FAU - Kandeel, Eman Z
AU  - Kandeel EZ
AD  - Department of Clinical Pathology, National Cancer Institute, Cairo University, 
      Cairo 11976, Egypt.
FAU - El-Habashy, Ahmed H
AU  - El-Habashy AH
AD  - Department of Pathology, National Cancer Institute, Cairo University, Cairo 
      11976, Egypt.
FAU - Salem, Mohamed L
AU  - Salem ML
AD  - Department of Zoology, Faculty of Science, Tanta University, Tanta, Gharbia 
      31511, Egypt.
FAU - El-Houseini, Motawa E
AU  - El-Houseini ME
AD  - Medical Biochemistry and Molecular Biology Unit, Department of Cancer Biology, 
      National Cancer Institute, Cairo University, Cairo 11976, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20180504
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6006460
OTO - NOTNLM
OT  - Foxp3
OT  - MCF-7 breast cancer cells
OT  - breast cancer
OT  - cytotoxic T-lymphocyte
OT  - dendritic cells
OT  - interferon-gamma
OT  - interleukin 12
OT  - lactate dehydrogenase
EDAT- 2018/06/22 06:00
MHDA- 2018/06/22 06:01
PMCR- 2018/05/04
CRDT- 2018/06/22 06:00
PHST- 2017/03/17 00:00 [received]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2018/06/22 06:00 [entrez]
PHST- 2018/06/22 06:00 [pubmed]
PHST- 2018/06/22 06:01 [medline]
PHST- 2018/05/04 00:00 [pmc-release]
AID - OL-0-0-8631 [pii]
AID - 10.3892/ol.2018.8631 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Jul;16(1):529-535. doi: 10.3892/ol.2018.8631. Epub 2018 May 4.